Kalkan, SerkanDemircan, SelcukDisli, Zeliha KorkmazDuzenci, DeccaneMemisoglu, FundaYalcinsoy, MuratBicakcioglu, Murat2026-04-042026-04-0420242667-663Xhttps://doi.org/10.4328/ACAM.22323https://hdl.handle.net/11616/108378Aim: Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Material and Methods: This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients' demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results: Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (p=0.010) and in the first week (p=0.001). The improvement in ferritin levels in the first week was significantly higher in Group T (p=0.018). Discussion: No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.eninfo:eu-repo/semantics/openAccessArdsCovid-19Cytokine Storm SyndromeIvigTocilizumabArticle151286587010.4328/ACAM.22323WOS:001424161100011Q4